| dc.description.abstract | Background : Asthma is the most common chronic heterogeneous disease of the respiratory tract In the Asia-Pacific region, the highest level of asthma control is partially controlled asthma at 63%, followed by uncontrolled asthma at 30% and fully controlled asthma at 7%. There is still little data regarding the ICS / LABA management profile in patients with moderate persistent asthma, especially in the Pulmonary Clinic of Prof. Chairuddin Panusunan Lubis USU Hospital
Objective : To determine the profile of ICS/LABA use according to the level of asthma control and demographic proportions in patients with moderate persistent asthma.
Methods : An analytic cohort retrospective study was performed by using medical records for 3 years (January 1, 2017, to December 31, 2019). Data collection was conducted from September 2023 to April 2024. The study subjects were patients with moderate persistent asthma who received ICS/LABA therapy for at least 3 months. Descriptive statistical analysis was used to assess the profile of ICS/LABA treatment on clinical outcomes.
Result : The sex was dominated by women as 48 people (78,7%), the age range> 41-50 years by 20 people (32,8%). The distribution of the highest level of educationis high school by 23 people (37,7%), the majority of respondents do not work by 29people (47,5%) and a history of not smoking by 60 people (98,4%). In thecharacteristics of treatment dominated by the ICS/LABA type of Salmeterol /Fluticasone propionate Diskus doses 50/250 mcg by 33 people (54,1%) and theICS/LABA types of Formoterol Fumarate/Budesonide dose of 4,5/160 mcg used by28 people (45,9%). The highest proportion of asthma control level was partiallycontrolled asthma by 44 people (70,5%) and a history of scheduled polyclinic visitsmade by 57 respondents (93,8%). Spiromtery test assessment obtained the largestfrequency distribution of FEV1 values was <60% by 31 people (50,8%) mean57,28, FVC value was 30 – 60% by 31 people (50,8%) mean 58,49 and FEV1/FVCvalues was > 75% by 49 people (80,3%) mean 80,59. Analytic statistical test resultsshowed that demographic factors are not associated with the level of asthmacontrol of respondent.
Conclusion : A varied management profile was obtained with the majority of ICS / LABA usage was the Salmeterol / Fluticasone propionate type at a dose of 50/250 mcg with most of the prevalence of sex was female and demographic factors not related to the level of asthma control. | en_US |
